The initiative of the current study was the unexpected complete tumor regression of a 31 patient with stage IV cutaneous metastatic melanoma, who suffered multifactorial sepsis 32 syndrome during BOLD chemotherapy (Suppl. Fig. 1.) . After targeted antibiotic treatment 33 and combined complication-free chemotherapy, the patient's physical condition improved 34 and-unexpectedly-the metastases disappeared. The patient has been asymptomatic and 35 metastasis-free ever since the end of BOLD therapy. A significant decrease in the volume of 36 the previously palpable axillary and abdominal metastases was observed already when BOLD 37 was interrupted due to sepsis. For a timeline of events, see Table 1 . 38
Molecular genetics research in the last decade helped the development of BRAF 39 inhibitors and immunooncological agents, which brought about a significant improvement of 40 the life expectancy of melanoma patients. Once the gold standard (Avril et al., 2004) , 41
Dacarbazine-based chemoterapies are still approved and widely applied in melanoma therapy, 42 but their efficacy is known to be relatively low (Garbe et al., 2011) . In the light of this, the 43 fact that clinical improvement was observed quite early during the chemotherapy suggested 44 other factors behind the outcome, and the concurrent sepsis seemed to offer a potential 45 explanation. 46 It has long been recognized that cancer patients might recover following bacterial 47 infections (Wiemann and Starnes, 1994; Hobohm, 2001) . The hypothesis was that fever and 48 TNF-α induced by the infectious agents caused the tumor regression, but this could not be 49 reproduced by TNF-α administration or hyperthermia (Nauts et al., 1946; Tsung and Norton, 50 2006) . It has been observed that an attenuated form of Listeria monocytogenes can infect 51 cancer cells, but not normal cells, and this phenomenon resulted in a potentially effective 52 experimental cancer therapy. (Quispe-Tintaya W et al.2013 ) 53 virus significantly decreased the incidence of melanoma (Krone et al., 2005) . However, a 55 convincing explanation is still missing. 56
While it is generally accepted that anti-tumor immune mechanisms overlap with anti-57 bacterial immune responses (Chen et al., 2007; Adams, 2009; ) , the exact mechanism induced 58 by microbes is not understood. 59
As immune responses appear to be decisive factors also in the outcome of melanoma 60 (Ridnour et al., 2013; Shimanovsky et al., 2013) , we hypothesized that sepsis, by triggering 61 polarized, "joint" anti-bacterial and anti-tumor immune responses, could induce tumor 62
regression. This hypothesis was tested in our experimental model. 63
To clarify the role of the adaptive immune system in the anti-tumor immune 64 mechanisms induced by C. pneumoniae (CP, successfully identified in the primary melanoma 65 after our patient recovered from sepsis-Suppl. Fig. 1f ), lung metastases (LM) were induced in 66 immunocompetent C57BL/6 mice or immunodeficient NSG mice. Animals were then CP-or 67 mock-treated (Suppl. Materials and methods). To assess the effects of treatment, histological, 68 immunological and molecular analyses were done. 69
70

Results
71
In immunocompetent, CP-treated animals, the number of LMs significantly decreased 72 (P=0.003) (Fig. 1a) , while the survival (Fig. 1t) significantly increased (P=0.04) compared to 73 mock treatment. This was not observed in immunodeficient mice, and the treated animals did 74 not develop fever (33.2 ºC±1.0 mock vs. 34.8 ºC±0.5 CP) or high plasma levels of TNF-α 75 either, which is against the "fever hypothesis" (Wiemann and Starnes, 1994; Hobohm, 2001) . 76
Histological analysis of slices from the lungs of mock-treated melanoma-bearing 77 immunocompetent mice showed a high number of LMs, with frequent intra-tumor necrosis 78 (Fig. 1e) . In contrast, fewer and smaller foci of regressive LMs were observed in the CP-79 treated immunocompetent animals (Fig. 1f) . Moreover, in this group, a high number of tumor-80 infiltrating mononuclear histiocytes and lymphoid cells were identified in the LMs. The LMs 81 did not exhibit significant intratumor immune reactions in the immunodeficient mice, 82 regardless of treatment type (Fig. 1g, h) . Markedly increased immune reaction in the lungs of 83 the CP-treated mice was also verified by immunolabeling of the cell surface activation 84 markers CD11b and CD80 (Fig. 1i-l) . Immune cell invasion was not detected after mock 85 treatment -the immune cells were concentrated in the marginal zones of the tumors (Fig. 1i,  86 k). In contrast, after CP treatment, marked infiltration by activated lymphocytes was seen in 87 the internal tumor stroma (Fig. 1j, l) ; differences were significant (Fig. 1m, n 
) (P=0.0001). 88
To assess macrophage polarization, M1 (anti-tumor) or M2 (pro-tumor) macrophage -89 specific cytokine and chemokine transcriptome profiling was done (Mantovani et al., 2004) . 90
Macrophage markers were detected with Q-PCR from pooled lung samples 2, 4 and 12 hours 91 after mock or CP treatment. Four hours after CP application, markedly increased levels of M1 92 -specific mRNA transcripts for CCL2, CCL3, IL6, CXCL10, CCL7, CD80, CXCL11, 93 CXCL9, IL23, and TNFα were detected. In line with this, the mRNA expression of most M2-94 specific markers decreased. Interestingly, the levels of some important M2 markers 95 (CXCL13, IL1Ra) were actually increased (Suppl. Fig. 2a, b) . Upon CP administration, the 96 quantity of M1-specific cytokine and chemokine mRNA was significantly increased 97 (P=0.014) after 4 hours, in comparison to M2-markers. 98 Alteration in the expression pattern of COX-1 and COX-2 is one of the key markers of 99 macrophage polarization (Martinez et al., 2006; Mantovani et al., 2013) . Western blot 100 analysis revealed that 12 hours after CP treatment, protein expression of the M2-specific 101 COX-1 decreased by half, whereas the protein expression of the M1-specific COX-2 102 increased more than two fold (Suppl. Fig. 2c, d ). Two hours after CP treatment -but not after mock treatment-CXCL1 melanoma 104 growth factor immunoreactivity become undetectable (Suppl. Fig. 3a, b) . To assess whether 105 this in vivo phenomenon was due to a direct CP:CXCL1 interaction, equal amounts of 106 recombinant CXCL1 were incubated in vitro (in the presence of protease inhibitors) with 107 increasing quantities of CP. CXCL1 levels were determined by Western blotting. CP depleted 108 CXCL1 in a dose-dependent manner, suggesting a strong and direct binding by CP (Suppl. 109 Fig. 3c, d) . 110
Discussion 111
Our results seem to indicate that CP treatment does indeed induce a complex anti-tumor 112 response. We showed that CP treatment can suppress LM formation in immunocompetent 113 (but not in immunodeficient) mice. M1-type macrophage polarization was demonstrated, 114 which is associated with anti-tumor effects (Sica et al., 2008) . The anti-tumor immune 115 polarization/activation was further supported by the profound enrichment of CD80 and 116
CD11b expressing immune cells in the lungs CP-treated animals (Prebeck et al., 2001) . Of 117 special importance, the melanoma growth factor CXCL1 was completely depleted by CP, 118 both in vivo and in vitro. 119
As (i) CXCL1-induced NF-κB activity was shown to facilitate melanoma transformation by 120 allowing melanocytes to escape apoptosis; and (ii) IκB-α ∆N (super-repressor of NF-κB) 121 reduced tumor growth and metastatic potential of melanoma cells (Dhawan et al., 2002) , we 122 consider it a possible scenario that not only the CP induced M1 type macrophage polarization 123 but the induced CXCL1 depletion could significantly contribute to the tumor regression. 124
Evidently, results of the animal study strongly support our assumption about the role of sepsis 125 in the observed outcome; however, these data cannot exclude the role of the BOLD therapy. 126
The conclusion one can safely draw at this point is that sepsis, in the context of BOLD, 127 The patient herself detected a bleeding nevus-like lesion on the back and an enlarged axillary lymph node; no steps were taken.
120
Hospital visit. X-ray, mammography and abdominal doppler seems to be negative, axillary lymph node biopsy was proposed. The patient was temporarily lost from follow up.
0
Hospital visit for abdominal pain, gastritis was diagnosed and a gastric polyp was removed. Tumor masses were discovered in the retroperitoneal lymph nodes (15-20 mm), spleen (67 mm) and bladder (40x68 mm). Another tumor was detected in the brain by CT (40 mm).
4
The intracranial tumor mass was removed surgically and diagnosed as amelanotic melanoma metastasis.
24
Cranial radiotherapy was initiated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 -C5a is a complement protein that has been implicated in tumorigenesis. C5a accelerates tumor progression, can directly activate myeloid-derived suppressor cells, stimulate angiogenesis and cell migration. C5a increases VEGF level, prevents the activation of apoptotic caspase 3 and DNA fragmentation, and may function as an anti-apoptotic molecule Gunn et al., 2012) . We found decreased levels of this protein after treatment.
-CD54 (ICAM-1) decreased in our in vivo model and expresses with a dose-and timedependent increase in human malignant melanoma cells on stimulation of TNF-alpha.
Inhibition of ICAM-1 expression on melanoma cells reduces the metastatic ability of the melanoma cells, indicating an important role of ICAM-1 in metastasis (Miele et al., 1994) . B.
Cava et al. described that metastasis reduction of B16 cells is correlated to the reduction of plasma gelatinolitic activity and to the decrease of cells expressing CD44, CD54, and integrin-β 3 adhesion molecules.
-CXCL1 is a melanoma growth factor and known as M2 marker. Our results suggest that the depletion of CXCL1 could play a role in the reduction of metastasis formation.
-MCP-1 (decreased in our model) is produced by a variety of tumors, including B16F1 and plays an important role in tumor progression, especially in angiogenesis Koga et al., 2008) . Tumor cell-activated macrophages release TNFα, which facilitates the -IL-16: it is a pleiotropic cytokine that functions as a chemoattractant, hence a modulator of T cell activation. The cytokine function is exclusively attributed to the secreted C-terminal peptide, while the N-terminal product may play a role in cell cycle control. Caspase 3 is reported to be involved in the proteolytic processing of this protein (http://www.cancerindex.org/geneweb/IL16.htm). IL-16 appears in the literature remarkably scarcely in connection with cancer, and we could not detect alteration in its level either; therefore, we do not know the relevance of this protein to the discussed observation.
-IL-1Ra (moderately decreased or unchanged in our model) is the receptor antagonist of IL-1 and it has been described as pleiotropic (Aubie et al., 2015; Di Mitri et al., 2014) . Although IL-1Ra has been described to inhibit subcutaneus B16 melanoma growth in vivo (McKenzie et al., 1996) we did not observe significant changes in its level upon treatment; therefore, similar to IL-16, the relevance of this finding is still unknown.
-CCL5 (decreased in our model) is a chemokine with tumor supportive properties (Adler et al., 2003; Sugasawa et al., 2008) . In rectal cancer, significant decrease of CCL5 was associated with a favorable response to chemoradiation therapy (Tada et al., 2014) . Moreover, Mdr2 and CCR5 (CCL5 receptor) double knock-out mice exhibited significant decrease in tumor incidence and size of hepatocellular carcinoma (Barashi et al., 2013) . Finally, CCL5 was found to enhance cytotoxicity of regulatory T cells against CD8+ cells (Chang et al., 2012) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Survival
For the survival experiments, groups of mice (n=15) were treated as described 5 times after melanoma implantation. Kaplan-Meier survival curves were analyzed by a log-rank statistical test and p ≤ 0.05 was regarded as statistically significant. The body temperatures of 3 animals/group were measured using an AMA Digital AD 15 TH thermometer 2 hours after the 1 st treatment and 4 hours after the 2 nd inhalation (day 7 and 9). All animal experiments were authorized by the institutional and national animal welfare committees.
Cytokine and Chemokine Expression Analysis by Quantitative Real-time PCR
Total RNA was purified using a NucleoSpin RNA II RNA isolation kit (Macherey-Nagel, 
Histology, immunohistochemistry
Lung specimens were fixed in 4% buffered formaldehyde; then routine HE histology as wells as standardized immunohistochemistry tissue microarray were performed using anti-CD11b
(clone M1/70; R&D Systems, Minneapolis, MN) and CD80 (B7-1; R&D Systems, Minneapolis, MN) antibodies.
Cytokine and chemokine detection by proteome profiling
Expression levels of different cytokines in pooled lung specimens were determined using Mouse Cytokine Array Panel A (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions.
Western blot analysis of COX-1 and COX-2
To determine COX-1/COX-2 balance, Western blot analysis was performed using the lung lysates. Samples of total proteins were resolved on NuPAGE 4-12% Bis-Tris Gel, and then transfered to a nitrocellulose membrane. The membrane was incubated with anti-COX-1
(1:250, R&D, Minneapolis, MN) mouse monoclonal antibody and anti-COX-2 (1:200, R&D, Minneapolis, MN) goat polyclonal antibody. After overnight incubation, the membranes were and incubated for one hour with peroxidase conjugated anti-mouse (1:1000, R&D, Minneapolis, MN) and anti-goat IgG (1:10000, Sigma, St. Louis, MO) and developed using Odyssey Fc chemiluminescence detection system (LiCor Bioscience, Lincoln, NE).
Western blot analysis of CXCL1
Recombinant mouse CXCL1 protein (0.5 µg, R&D Systems, Minneapolis, MN) was mixed and incubated (37°C, 30 min) with different 10-fold (10-10000) dilutions of C. pneumoniae solutions (3.6 µg-0.00036 µg). CXCL1 protein amounts were then detected by Western blot analysis using an anti-CXCL1 antibody (1:1000, R&D Systems, Minneapolis, MN).
Statistical analysis
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